Abstract
A novel antibiotic 210-A, named as (6S,8aS,9S,11S,12aR)-6-hydroxy-9,10-dimethyldecahydrobenzo[d]azecine-2,4,12(3H)-trione, was isolated from the fermentation broth of Streptomyces noursei Da07210, its structure was unambiguously established by spectral analyses and chemical comparison with related cycloheximide. Experiments demonstrated that 210-A bore strong activity against Fusarium oxysporum f. sp. cubense race four (Foc race four), which also showed antitumor activity against SMMC-7721 human hepatocarcinoma cells and S180 murine sarcoma, and the IC(50) values were 0.77 and 0.74 microg/ml, respectively.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / chemistry
-
Antibiotics, Antineoplastic / isolation & purification*
-
Antibiotics, Antineoplastic / pharmacology*
-
Antifungal Agents / chemistry
-
Antifungal Agents / isolation & purification*
-
Antifungal Agents / pharmacology*
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry
-
Bridged Bicyclo Compounds, Heterocyclic / isolation & purification*
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Cell Line, Tumor
-
Fusarium / drug effects
-
Humans
-
Inhibitory Concentration 50
-
Mice
-
Microbial Sensitivity Tests
-
Spectrum Analysis
-
Streptomyces / chemistry*
Substances
-
6-hydroxy-9,10-dimethyldecahydrobenzo(d)azecine-2,4,12(3H)-trione
-
Antibiotics, Antineoplastic
-
Antifungal Agents
-
Bridged Bicyclo Compounds, Heterocyclic